The s-AML group is heterogeneous at the mutational level in that a part of these patients (about 11%) displays TP53 mutations, the majority (about 66%) secondary-type mutations and the rest (about 23%) in that part possess de novo-like AML-related mutations, such as NPM1 mutations [63]. Here, TP53 is linked to acute myeloid leukemia.